Massachusetts medical device maker Boston Scientific (NYSE:BSX) has a new partner in Israel, agreeing to supply a slate of its products through local distributor Amos Gazit Ltd
Amos will provide services for Boston Scientific’s urology and women’s health, endoscopy, peripheral interventions and interventional cardiology products, with the exception of the Watchman left atrial appendage occlusion device.
The partnership was reached with Amos and Israeli marketing firm Medison, according to a press release.
Boston Scientific has been making headway around the world, recently announcing the 1st implant of its lead-free S-ICD heart rhythm implant in China, a launching board for broader efforts in Asia.
The company has also notched recent European Union approvals for its Rebel bare-metal stent, its Ingevity line of MRI-safe pacemaker leads and its Expect Slimline needle, all within the last 30 days.
BSX shares got a boost today, gaining 4.1% to trade at $13.44 as of about 1:45 p.m. The stock has gained 11.7% since the start of the year.
